Voriconazole (Vfend 威凡) 0.2g | Pfizer China Originator | GLT

Generic Information: Vfend 威凡 (China)

This listing is the China-market presentation of Vfend, Pfizer's originator voriconazole, marketed locally under the Chinese trade name 威凡 (Wei Fan) and approved by the National Medical Products Administration. Supplied as ten 0.2 g film-coated tablets per box, it is the same reference molecule used in Europe and the United States for life-threatening mould and yeast infections.

What Is Voriconazole (Vfend) Used For?

Voriconazole is prescribed for invasive fungal disease in immunocompromised patients: invasive aspergillosis, candida bloodstream infection in non-neutropenic patients, oesophageal candidiasis, and serious Fusarium or Scedosporium infections. In China it anchors the antifungal strategy of haematology wards, lung transplant units and intensive-care departments, where broad-spectrum mould coverage must begin while the organism is still being identified.

How Does Voriconazole Work?

The drug disrupts ergosterol synthesis, the building block of the fungal cell membrane. By inhibiting the fungal cytochrome enzyme that converts lanosterol to ergosterol, voriconazole collapses membrane integrity and halts fungal growth, with fungicidal activity against many Aspergillus strains. Its selectivity for the fungal enzyme — not the human counterpart — underpins a tolerable safety profile at therapeutic doses.

Indications

Clinical use covers invasive aspergillosis, candidemia and deep-tissue candidiasis in non-neutropenic patients, oesophageal candidiasis, and refractory Fusarium or Scedosporium apiospermum infection. Prescribers confirm the pathogen with culture, antigen testing or molecular methods, and often measure drug blood levels because absorption and metabolism differ markedly from one patient to another.

Dosage

The standard adult regimen opens with a loading dose of 6 mg/kg every 12 hours for the first day, followed by oral maintenance of 200 mg every 12 hours — exactly one 0.2 g tablet each dose, twice daily. Patients below 40 kg use 100 to 150 mg every 12 hours, and those with mild-to-moderate liver impairment take half the maintenance dose. Tablets are swallowed whole, ideally one hour before or after food for the most consistent absorption.

Side Effects

The signature early effect is reversible visual disturbance — blurred vision, altered colour perception or photophobia — reported in up to a third of patients and usually resolving despite continued therapy. Other common events are rash, nausea, headache, fever and raised liver enzymes. Important safety signals requiring prompt attention include liver toxicity, QT prolongation, and fluorosis-like skin or bone changes with prolonged use, so monitoring is routine.

Storage

威凡 tablets are kept at room temperature in their sealed aluminium-plastic blister packs, protected from light and humidity; no cold chain is needed. GLT dispatches the Chinese originator presentation by ambient express from a Hong Kong-licensed facility, each order accompanied by full documentation.

Why Choose Vfend 威凡 Through GLT?

The China presentation delivers Pfizer's genuine voriconazole at a locally regulated pack size of ten tablets, convenient for individual treatment courses and self-funded patients. Sourced through GLT's Hong Kong base, it carries NMPA-approval provenance and batch traceability, with delivery routes optimised for the Asia region.

How to Order

To order the China-market Vfend 威凡 (voriconazole), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. We confirm availability, quantity pricing and shipping to your country before payment, and ship from a Hong Kong-licensed facility.

FAQ

What is 威凡? 威凡 (Wei Fan) is the Chinese trade name of Vfend, Pfizer's originator voriconazole approved by the NMPA.

How many tablets per box? Ten 0.2 g (200 mg) film-coated tablets per box — a five-day supply at the standard twice-daily maintenance dose.

Is the Chinese Vfend the same as the US product? Yes — identical molecule and 200 mg strength; only local packaging and regulatory presentation differ.